search
Back to results

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST) (TRUST)

Primary Purpose

Pulmonary Embolism

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Laguna Thrombectomy System
Sponsored by
Innova Vascular, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Embolism focused on measuring Laguna Thrombectomy System, Pulmonary Embolism

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: ≥ 18 years of age; < 85 years old RV/LV ratio > 0.9 as determined by CTA Systolic blood pressure > 90 mmHg Heart rate ≤ 120 Patient is deemed eligible for procedure by the interventional investigator CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery) PE Symptom duration ≤ 14 days Exclusion Criteria: Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments Life expectancy of < 90 days in the opinion of investigator at the time of enrollment Subject pregnant or breast feeding Current participation in another drug or medical device treatment study In active chemotherapy or radiation treatment for a malignancy during the course of the study Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium History of prior PE within the past 90 days FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90% Hematocrit: < 28% Platelets: < 100,000/microliter Serum Creatinine: > 2 mg/dL International Normalized Ratio (INR): > 3 Major Trauma Injury Severity Score (ISS): > 15 Cardiovascular or pulmonary surgery within the last 7 days Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation History of known severe or chronic pulmonary arterial hypertension History or chronic left heart disease with left ventricular ejection fraction < 30% History of underlying lung disease that is oxygen dependent History of chest irradiation Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus) Known presence of clot in transit within right atrium or ventricle

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Laguna Thrombectomy System

    Arm Description

    Outcomes

    Primary Outcome Measures

    A composite of the following major adverse events occurring within 48 (± 8) hours post-procedure:
    Device-related death within 48 (± 8) hours post-procedure Major bleeding as defined by GUSTO (moderate or severe) within 48 (± 8) hours post-procedure. The following treatment-related adverse events within 48 (± 8) hours post-procedure: Cardio-respiratory deterioration, Pulmonary vascular injury, and/or Cardiac injury
    Reduction in RV/LV ratio from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) as assessed by Computed Tomography Angiography (CTA)

    Secondary Outcome Measures

    Full Information

    First Posted
    September 11, 2023
    Last Updated
    September 11, 2023
    Sponsor
    Innova Vascular, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06041594
    Brief Title
    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
    Acronym
    TRUST
    Official Title
    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    December 2023 (Anticipated)
    Primary Completion Date
    December 2024 (Anticipated)
    Study Completion Date
    June 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Innova Vascular, Inc.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pulmonary Embolism
    Keywords
    Laguna Thrombectomy System, Pulmonary Embolism

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    107 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Laguna Thrombectomy System
    Arm Type
    Experimental
    Intervention Type
    Device
    Intervention Name(s)
    Laguna Thrombectomy System
    Intervention Description
    Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism
    Primary Outcome Measure Information:
    Title
    A composite of the following major adverse events occurring within 48 (± 8) hours post-procedure:
    Description
    Device-related death within 48 (± 8) hours post-procedure Major bleeding as defined by GUSTO (moderate or severe) within 48 (± 8) hours post-procedure. The following treatment-related adverse events within 48 (± 8) hours post-procedure: Cardio-respiratory deterioration, Pulmonary vascular injury, and/or Cardiac injury
    Time Frame
    within 48 (± 8) hours post-procedure
    Title
    Reduction in RV/LV ratio from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) as assessed by Computed Tomography Angiography (CTA)
    Time Frame
    from baseline to 48 (± 8) hours (or at discharge, whichever occurs first)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: ≥ 18 years of age; < 85 years old RV/LV ratio > 0.9 as determined by CTA Systolic blood pressure > 90 mmHg Heart rate ≤ 120 Patient is deemed eligible for procedure by the interventional investigator CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery) PE Symptom duration ≤ 14 days Exclusion Criteria: Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments Life expectancy of < 90 days in the opinion of investigator at the time of enrollment Subject pregnant or breast feeding Current participation in another drug or medical device treatment study In active chemotherapy or radiation treatment for a malignancy during the course of the study Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium History of prior PE within the past 90 days FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90% Hematocrit: < 28% Platelets: < 100,000/microliter Serum Creatinine: > 2 mg/dL International Normalized Ratio (INR): > 3 Major Trauma Injury Severity Score (ISS): > 15 Cardiovascular or pulmonary surgery within the last 7 days Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation History of known severe or chronic pulmonary arterial hypertension History or chronic left heart disease with left ventricular ejection fraction < 30% History of underlying lung disease that is oxygen dependent History of chest irradiation Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus) Known presence of clot in transit within right atrium or ventricle
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Sanjay Shrivastava, Ph.D.
    Phone
    949-295-6040
    Email
    ss@innovavascular.com

    12. IPD Sharing Statement

    Learn more about this trial

    Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

    We'll reach out to this number within 24 hrs